Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the possibility of early interception is a growing area of interest in the field.

In this week’s podcast, you will hear from Shaji Kumar, MD, Mayo Clinic, Rochester, MN, Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, and Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, who discuss novel technologies being explored to risk stratify individuals with SMM and MGUS. Following this, Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, Kwee Yong, PhD, FRCP, FRCPath, University College London, London, UK, and Omar Nadeem, MD, Dana-Farber Cancer Institute, Boston, MA, discuss the possibility of early interception in SMM, highlighting ongoing trials in the field. This episode is part of our podcast series from the 2024 Intercepting Blood Cancers (IBC) Workshop, which was held in Lisbon, Portugal.

The post Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification appeared first on VJHemOnc.